NGM Biopharmaceuticals: Top 5 Biotech VC, H1 2010

Company: NGM Biopharmaceuticals
Based: South San Francisco, CA
Amount: $51M

Investors: The Column Group, Tichenor Ventures, Prospect Venture Partners, Rho Ventures

Scoop: NGM has developed a drug discovery platform based on the company's observations of patient results following gastric bypass surgery. People who undergo gastric bypass often experience immediate remission of diabetes, even before they've lost significant weight. Its gastrointestinal program is designed to understand and mimic the effects of bariatric surgery-induced diabetes remission.

Related Articles:
NGM lands $51M for preclinical diabetes work